HLH is a frequently fatal, rare disease caused by an overactive, abnormal response of the immune cells. As per John Hopkins Medicine, there are two types of HLH, familial and acquired. Familial HLH accounts for about 25% of cases..
According to the NORD, in adults, men are slightly more affected than females. The total Hemophagocytic Lymphohistiocytosis (HLH) incident population in seven major markets (i.e. the US, EU5 (the UK, Germany, France, Spain and Italy), and Japan) was 4,435 in 2017.
Early diagnosis and treatment can cut any ice in case of Hemophagocytic Lymphohistiocytosis (HLH) as, without prompt treatment, the condition is often fatal. However, the treatment market lacks the availability of standard treatment along with the challenge of underdiagnosis.
Several novel drug candidates in monotherapies as well as in combinations are under evaluation for Hemophagocytic Lymphohistiocytosis (HLH) treatment, with its candidate therapy Tadekinig Alfa, the AB2 Bio Ltd. is the leading player in the Hemophagocytic Lymphohistiocytosis (HLH) market.
Source: Hemophagocytic Lymphohistiocytosis (HLH) Treatment Market